Tapinarof Cream 1% Once Daily for Plaque Psoriasis: Long-Term Extension Trial of a Novel Therapeutic Aryl Hydrocarbon Receptor Modulating Agent

Main Article Content

Bruce Strober
Yale University, New Haven & Central Connecticut Dermatology Research, Cromwell, CT, USA,

Linda Stein Gold
Henry Ford Health System, Detroit, MI, USA

Robert Bissonnette
Innovaderm Research Inc., Montreal, QC, Canada

April Armstrong
Keck School of Medicine at University of Southern California, Los Angeles, CA, USA

Andrew Blauvelt
Oregon Medical Research Center, Portland, OR, USA

Philip Brown
Dermavant Sciences, Inc., Morrisville, NC, USA

Leon Kircik
Mount Sinai

Anna Tallman
Dermavant Sciences, Inc., Morrisville, NC, USA

Mark Lebwohl
Mount Sinai

Keywords

tapinarof, psoriasis, long term extension trial

Abstract

N/A

References

1. Lebwohl M, et al. Skin. 2020;4(6):s75;

2. Robbins K et al. J Am Acad Dermatol. 2019;80:714–721;

3. Strober B, et al. Innovations in Dermatology Virtual Spring Conference 2021, Poster Presentation,
March 16–20, 2021.

Article Sidebar

Poster PDF
Published
Nov 5, 2021
DOI https://doi.org/10.25251/skin.5.supp.35

Article Details

How to Cite
Strober , B., Stein Gold, L., Bissonnette, R., Armstrong , A., Blauvelt, A. ., Brown, P. ., Kircik, L. ., Tallman, A., & Lebwohl, M. (2021). Tapinarof Cream 1% Once Daily for Plaque Psoriasis: Long-Term Extension Trial of a Novel Therapeutic Aryl Hydrocarbon Receptor Modulating Agent. SKIN The Journal of Cutaneous Medicine, 5(6), s35. https://doi.org/10.25251/skin.5.supp.35
Issue
Vol. 5 No. 6 (2021): November Issue & Poster Presentations (FC21 Dermatology Conference®)
Section
Poster Presentations from FC21 Dermatology Conference®: Psoriasis
Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

All authors retain copyright in their articles. All articles published open access allowing for immediate free access to the work and permitting any user to read, download, copy, distribute, print, search, or link to the full texts of articles, crawl them for indexing, pass them as data to software or use them for any other lawful purpose. Permitted reuse is defined by  the following user license:
 

Creative Commons Attribution (CC BY): lets others distribute and copy the article, to create extracts, abstracts, and other revised versions, adaptations or derivative works of or from an article (such as a translation), to include in a collective work (such as an anthology), to text or data mine the article, even for commercial purposes, as long as they credit the author(s), do not represent the author as endorsing their adaptation of the article, and do not modify the article in such a way as to damage the author's honor or reputation. 

Authors retain copyright in their work and license the publisher to publish the content. The publisher is the National Society for Cutaneous Medicine, with production and publishing support provided by OJS, Open Journal Systems,see https://pkp.sfu.ca/ojs/.

Prior to January 2022, authors transferred copyright to the National Society for Cutaneous Medicine. However, all articles are freely available to anyone in the world. There are no subscription fees, page charges, or article processing charges.

Most read articles by the same author(s)

<< < 1 2 3 4 5 6 7 8 9 10 > >>